Posts by: Diana Campelo Delgado

Diana Campelo Delgado

Diana holds a PhD in Biomedical Sciences, with specialization in genetics, from Universidade Nova de Lisboa, Portugal. Her work has been focused on enzyme function, human genetics and drug metabolism.

November 11, 2020November 11, 2020

Amazonian Tea Component Stimulates New Nerve Cell Formation, Study Suggests

News

Dimethyltryptamine or DMT, one of the main natural components of traditional Amazonian ayahuasca tea, promotes the formation of new nerve cells (neurogenesis), a recent study suggests. Researchers say the ... Read more

November 10, 2020November 10, 2020

Rare Neurodegenerative Disorder May Share Similar Genetic Mutation With Parkinson’s

News

A rare neurodegenerative disorder called neuronal intranuclear inclusion body disease (NIID) may share a similar genetic mutation with Parkinson’s disease (PD), a study suggests. Patients who present with typical Parkinson’s ... Read more

November 9, 2020November 9, 2020

Phase 1 Trial of Stem Cells in Treating Bradykinesia to Open in US

News

A Phase 1 clinical trial evaluating umbilical cord-derived mesenchymal stem cells (MSCs) as a potential treatment of bradykinesia — slowness or difficulty with movement — in people with Parkinson’s disease is expected ... Read more

November 6, 2020November 9, 2020

First Patients Enrolled in Phase 3 Trial Investigating ABBV-951 for Parkinson’s

News

The first two patients have been enrolled in AbbVie‘s Phase 3 clinical trial evaluating the safety and effectiveness of its investigational therapy ABBV-951 for treating motor fluctuations in advanced Parkinson’s ... Read more

November 5, 2020November 5, 2020

Ways of Preventing Protein Clumping in Parkinson’s Goal of Swiss Partnership

News

The Brain Mind Institute has joined with Idorsia Pharmaceuticals in a three-year effort to discover and develop new therapies for Parkinson’s disease and other neurodegenerative disorders. “This collaboration combines some of ... Read more

October 19, 2020October 19, 2020

Anavex 2-73 Safely Aids Cognition in Parkinson’s Dementia, Phase 2 Trial Reports

News

Anavex 2-73 (blarcamesine), a potential oral therapy to slow cognitive decline due to Alzheimer’s and other neurological disorders, was found to be safe and to lead to clinically meaningful, dose-dependent improvements ... Read more

October 15, 2020October 15, 2020

Study Delves Into Genetic, Environmental Risk Factors for Parkinson’s

News

The interplay between different genetic and environmental factors, from a family history of disease to smoking habits, contributes to Parkinson’s risk and can help in designing tests that better ... Read more

October 14, 2020October 14, 2020

Innovative Tool Identifies New Alpha-synuclein PET Tracers for Parkinson’s

News

An innovative computational approach for identifying new alpha-synuclein tracer molecules could be used to track the progression of Parkinson’s disease, according to a recent study. The study, “Identification of a ... Read more

October 13, 2020October 13, 2020

CLR01 ‘Molecular Tweezer’ Shows Potential to Slow Parkinson’s Progression

News

A new compound called CLR01, which works like a “molecular tweezer” to clear toxic protein clumps that accumulate in brain cells, could become a promising therapy to slow Parkinson’s ... Read more

October 13, 2020October 13, 2020

Risk of Recurrent Falls Evident in Elderly With Gait, Cognitive Problems

News

Previous falls, hallucinations, and cognitive problems are among the factors that predict a risk of recurrent falls in elderly people with parkinsonian gait, a study suggests. The study, “Parkinsonian gait ... Read more